NCT00004306

Brief Summary

OBJECTIVES: I. Clinically evaluate members from families with a dominantly inherited ataxia and collect blood, skin and muscle samples for detailed molecular studies. II. Perform detailed clinical evaluations on patients with recessively inherited ataxias.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 1999

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 18, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 19, 1999

Completed
13 days until next milestone

Study Start

First participant enrolled

November 1, 1999

Completed
9.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2009

Completed
Last Updated

March 6, 2012

Status Verified

March 1, 2012

Enrollment Period

9.3 years

First QC Date

October 18, 1999

Last Update Submit

March 5, 2012

Conditions

Hereditary Ataxia

Keywords

hereditary ataxianeurologic and psychiatric disordersrare disease

Eligibility Criteria

Age3 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with inherited ataxia

You may qualify if:

  • Subjects who have the diagnosis of SCA10 and their immediate relatives.

You may not qualify if:

  • Children under 3 years of age, pregnant women, prisoners, mentally incapacitated subjects, and subjects who do not give consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Medical Branch at Galveston

Galveston, Texas, 77555, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

DNA from blood and skin and muscle biopsy samples.

MeSH Terms

Conditions

Spinocerebellar DegenerationsNeurologic ManifestationsMental DisordersRare Diseases

Condition Hierarchy (Ancestors)

Cerebellar DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesSpinal Cord DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSigns and SymptomsPathological Conditions, Signs and SymptomsDisease AttributesPathologic Processes

Study Officials

  • Tetsuo Ashizawa, MD

    University of Texas, Galveston

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor and Chair, Department of Neurology, The University of Texas Medical Branch

Study Record Dates

First Submitted

October 18, 1999

First Posted

October 19, 1999

Study Start

November 1, 1999

Primary Completion

March 1, 2009

Study Completion

March 1, 2009

Last Updated

March 6, 2012

Record last verified: 2012-03

Locations

US(1)